Michelle Gilson
Stock Analyst at Morgan Stanley
(1.12)
# 3,757
Out of 5,182 analysts
32
Total ratings
34.48%
Success rate
-6.33%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Michelle Gilson
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| VIR Vir Biotechnology | Maintains: Overweight | $20 → $24 | $10.28 | +133.46% | 5 | Feb 24, 2026 | |
| CORT Corcept Therapeutics | Initiates: Buy | $30 | $46.62 | -35.65% | 1 | Feb 2, 2022 | |
| RZLT Rezolute | Maintains: Buy | $30 → $17 | $3.07 | +453.75% | 2 | Nov 29, 2021 | |
| ASND Ascendis Pharma | Maintains: Buy | $190 → $196 | $222.08 | -11.74% | 5 | Jun 1, 2021 | |
| TVTX Travere Therapeutics | Maintains: Buy | $48 → $45 | $40.89 | +10.05% | 3 | May 27, 2021 | |
| STOK Stoke Therapeutics | Maintains: Buy | $72 → $76 | $33.33 | +128.02% | 4 | Mar 11, 2021 | |
| BMRN BioMarin Pharmaceutical | Maintains: Buy | $95 → $91 | $53.30 | +70.73% | 12 | Mar 1, 2021 |
Vir Biotechnology
Feb 24, 2026
Maintains: Overweight
Price Target: $20 → $24
Current: $10.28
Upside: +133.46%
Corcept Therapeutics
Feb 2, 2022
Initiates: Buy
Price Target: $30
Current: $46.62
Upside: -35.65%
Rezolute
Nov 29, 2021
Maintains: Buy
Price Target: $30 → $17
Current: $3.07
Upside: +453.75%
Ascendis Pharma
Jun 1, 2021
Maintains: Buy
Price Target: $190 → $196
Current: $222.08
Upside: -11.74%
Travere Therapeutics
May 27, 2021
Maintains: Buy
Price Target: $48 → $45
Current: $40.89
Upside: +10.05%
Stoke Therapeutics
Mar 11, 2021
Maintains: Buy
Price Target: $72 → $76
Current: $33.33
Upside: +128.02%
BioMarin Pharmaceutical
Mar 1, 2021
Maintains: Buy
Price Target: $95 → $91
Current: $53.30
Upside: +70.73%